Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

20
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
20
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

23
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
23
Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

21
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
21
Complement System01:27

Complement System

11.0K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
11.0K
Complementation Tests00:49

Complementation Tests

6.3K
A complementation test is a simple cross to identify whether the two mutations are located on the same gene or different genes. It was first performed by Edward Lewis in the 1940s while working on fruit flies. He developed the test to identify the location and arrangement of different mutations on chromosomes.
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
6.3K
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

16
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
16

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advances in analytical methods for regulatory complement proteins in research and clinical applications.

Talanta·2026
Same author

Multi-omics and experimental evidence in human chondrocytes identify caspase-8 as a non-apoptotic regulator of inflammatory, senescent, and fibrotic signaling in osteoarthritis.

Cell communication and signaling : CCS·2026
Same author

A Comprehensive Immune Checkpoint Phenotype Predicts Response and Survival to PD-1 Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Head & neck·2026
Same author

Engineering Liposomes and Polymer Conjugates: A Platform for Mechanistic Complement Activation Studies and Controlled Release Applications.

ACS applied materials & interfaces·2026
Same author

Molecular dynamics of Brodmann Area 22 in development and autism.

bioRxiv : the preprint server for biology·2026
Same author

Increased LAG-3, TIM-3, and IDO1 Expression Is Associated With Oral Squamous Cell Carcinoma in Never Smokers and Never Drinkers.

Oral diseases·2026

Related Experiment Video

Updated: Feb 14, 2026

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids
10:43

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids

Published on: December 23, 2022

4.1K

A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma.

Juliane Gallenkamp1, Gerrit Spanier1, Elisabeth Wörle2

  • 1University Hospital Regensburg, Department of Oral and Maxillofacial Surgery, Regensburg, Germany.

Oncotarget
|February 10, 2018
PubMed
Summary

Researchers developed a novel assay to measure complement system activation in oral cancer patients. Elevated C5a and sC5b-9 levels indicate oral squamous cell carcinoma (OSCC) progression, offering potential diagnostic biomarkers.

Keywords:
C3aC5acomplement proteinsmulitplex assayoral squamous cell carcinoma

More Related Videos

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma
12:03

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

20.0K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

28.3K

Related Experiment Videos

Last Updated: Feb 14, 2026

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids
10:43

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids

Published on: December 23, 2022

4.1K
Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma
12:03

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

20.0K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

28.3K

Area of Science:

  • Immunology
  • Oncology
  • Biomarker Discovery

Background:

  • Oral squamous cell carcinoma (OSCC) is a prevalent oral malignancy requiring improved diagnostic and prognostic tools.
  • The complement system, a crucial part of innate immunity, plays a role in inflammation and cancer progression.
  • Investigating complement activation in OSCC could reveal novel biomarkers for early detection and monitoring.

Purpose of the Study:

  • To develop and validate an innovative multiplex assay for detecting complement activation products (C3a, C5a, sC5b-9) in OSCC patients.
  • To assess the correlation between complement activation levels and OSCC progression, including tumor differentiation, extension, and local spreading.
  • To evaluate the potential of complement activation markers as diagnostic and prognostic biomarkers for OSCC.

Main Methods:

  • Development of a suspension bead array using characterized antibodies for C3a, C5a, and sC5b-9 detection.
  • Analysis of human serum samples from healthy controls (n=46) and OSCC patients (n=57).
  • Validation of the assay's sensitivity, specificity, and precision using biological cut-off levels and statistical analysis.

Main Results:

  • The multiplex assay successfully detected C3a, C5a, and sC5b-9 in serum, tears, and aqueous humor with high sensitivity.
  • OSCC patients exhibited significantly increased systemic concentrations of C5a (p < 0.0001) and sC5b-9 (p = 0.01) compared to healthy controls.
  • Elevated C5a levels correlated with tumor differentiation and OSCC extension, while sC5b-9 indicated infiltrating tumor growth and C3a associated with local spreading.

Conclusions:

  • The validated multiplex complement activation assay is a sensitive tool for detecting key complement fragments.
  • Systemic complement activation, particularly elevated C5a and sC5b-9, serves as a promising biomarker for assessing OSCC progression and tumor characteristics.
  • These findings suggest the potential utility of complement activation markers in the clinical management of oral squamous cell carcinoma.